Evotec wins German government research grant

Published: 18-Nov-2009
Media

Granted up to €2.5m to advance research and development activities on the Serine Racemase target


Evotec has been granted up to €2.5m to advance research and development activities on the Serine Racemase target for potential use in neuroprotection.

The funds have been granted by the German Federal Ministry of Education and Research (BMBF) as part of its Pharmaceuticals Initiative for Germany, which aims to give new impetus to Germany's biotechnology and biopharmaceutical industry. In this initiative, consortia consisting of small and large companies and partners from science and clinical practice are eligible to submit a joint strategy for effective drug development.

Evotec is part of the New Materials Against Neurological Diseases (Neu2) consortium, which is focused on combatting multiple sclerosis. Neu2 includes Evotec, MerckSerono, the European ScreeningPort, Bionamics, and the University Medical Centre Hamburg-Eppendorf.

Evotec will use its drug discovery platform and expertise in progressing the Serine Racemase programme towards the clinic using its compound library and proprietary fragment-based drug discovery platform.

"This grant represents a valuable alternative to financing our research without jeopardising our patent position," said Dr Klaus Maleck, chief financial officer of Evotec.

See more

You may also like

Media

Evotec to acquire Aptuit, expanding leadership in external innovation

Read more
Evotec and Aptuit have entered into a definitive agreement, Evotec will acquire Aptuit for US$ 300 million

Trending Articles

  1. Can Aztekin receives Rising Star Award 2025 from the International Society of Regenerative Biology
  2. Royal Society of Chemistry and TIB co-create next generation Open Access consortium model The agreement delivers shared goals of equity for institutions, a community approach and universal open access for authors
  3. BioIVT acquires Optivia Biotechnology The acquisition strengthens BioIVT’s transporter sciences capabilities and will enable it to partner with customers on new drug applications and mechanistic studies related to transporters
  4. The Lab Awards: from balances to the ball The Lab Awards, the leading awards ceremony for the UK’s laboratory industry, was held at The Vox, Birmingham, on 1 November and celebrated the lab industry’s key achievements from the past year
  5. Reaping the benefits of a continuous process Growing interest in continuous processing reflects expectations that technological innovation can benefit operations across the board, says Guy Tiene, That’s Nice Director of Strategic Content

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Media

Evotec to acquire Aptuit, expanding leadership in external innovation

Evotec and Aptuit have entered into a definitive agreement, Evotec will acquire Aptuit for US$ 300 million
Media

Evotec acquires Indian RSIPL

<p>Evotec has expanded its capacity with the acquisition of drug discovery service company Research Support International Private (RSIPL) for Euro 2.8m (US$4m;
Media

Evotec acquires Zebrafish screening operations from Summit

<p>Evotec has acquired the Zebrafish screening business of Summit Corporation, including operations in Abingdon, UK, and Singapore for
Media

Evotec to close US operation and focus r&d in Europe

<p>Evotec, a German leader in the discovery and development of small molecule drugs, is reorganising its drug discovery and development operations and plans to concentrate all proprietary core research programmes in Europe. </p>
Media

Evotec to cut jobs and reduce costs following business review

<p>Evotec, a German leader in the discovery and development of novel small molecule drugs, is to restructure and significantly reduce its operating costs following a strategic business review.</p>
Media

Evotec to acquire Renovis

<p>Evotec and Renovis have entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases, in a stock-for-stock transaction valued at approximately US$151.8m.</p>
Media

Cherwell to be renamed AnalytiChem UK

Cleanroom microbiology expert, Cherwell, to become AnalytiChem UK Ltd from 1 September 2025
Subscribe now